• Teva Pharmaceutical Industries Ltd., of Petach Tikva, Israel, said the FDA approved Treanda (bendamustine HCl) injection, a new formulation of currently approved Treanda, indicated for use in patients with indolent B-cell non-Hodgkins’ lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a Rituxan-containing regimen and in patients with chronic lymphocytic leukemia. Teva acquired Treanda through its 2011 buyout of Cephalon Inc.